Oncology

News

Boundless Bio raises $100m for circular DNA cancer therapy

Boundless Bio’s plans to develop a new class of cancer therapies targeting DNA found outside the nucleus of malignant cells have been boosted by a $100 million fundraising

News

And Astellas’ latest drug discovery partner is… Sony?

Astellas Pharma has looked outside of the box for its latest cancer drug development partnership, joining forces with Sony on a project to find new antibody-drug conjugate

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Novartis cuts 10% of R&D projects in ‘focused’ strategy

Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat

Boundless Bio raises $100m for circular DNA cancer therapy

And Astellas’ latest drug discovery partner is… Sony?

AstraZeneca builds in cancer ADCs again, with LaNova deal

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

XinThera buy builds Gilead’s cancer, inflammation pipeline

Novartis cuts 10% of R&D projects in ‘focused’ strategy

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks